Core Insights - Vaccinex, Inc. is presenting new data on pepinemab, a monoclonal antibody targeting SEMA4D, which enhances immune responses in neoadjuvant settings for head and neck cancer [2][5][6] - The upcoming presentation at the ASCO conference will detail how pepinemab treatment correlates with improved pathologic responses by inducing mature lymphoid structures [4][6] Company Overview - Vaccinex, Inc. is focused on innovative treatments for cancer and neurodegenerative diseases through the inhibition of SEMA4D [8] - The lead drug candidate, pepinemab, is designed to block SEMA4D, which is implicated in immune cell infiltration and activation in tumors [7][9] Clinical Research and Development - Pepinemab is being evaluated in combination with other immunotherapies, such as KEYTRUDA and BAVENCIO, in various clinical trials for head and neck cancer and pancreatic adenocarcinoma [9][10] - Previous studies indicate that pepinemab can enhance immune cell interactions and improve treatment outcomes in patients with "cold" tumors, which are typically resistant to standard immunotherapy [5][6] Upcoming Events - The ASCO conference presentation is scheduled for June 1, 2025, focusing on the neoadjuvant biomarker trial of pepinemab in resectable head and neck cancer [4][5]

Core Insights - Pepinemab, a Semaphorin 4D blocking immunotherapy, shows promise in enhancing immune responses and improving survival in patients with metastatic melanoma and head and neck cancer [1][2][4][5]. Company Overview - Vaccinex, Inc. is a clinical-stage biotechnology company focused on innovative treatments for cancer and Alzheimer's disease through the inhibition of Semaphorin 4D [2][8]. - The lead drug candidate, pepinemab, is designed to block SEMA4D, which is believed to prevent immune cell infiltration in tumors and trigger inflammation in neurodegenerative diseases [8]. Clinical Data and Presentations - New data on pepinemab's mechanism to enhance immune responses will be presented at the 2025 AACR Annual Meeting, highlighting its role in improving clinical outcomes in combination with immune checkpoint therapies [2][3]. - Previous studies indicate that pepinemab enhances the maturity of tertiary lymphoid structures (TLS), correlating with longer recurrence-free survival in metastatic melanoma patients [5][6]. Mechanism of Action - Pepinemab facilitates immune cell interactions by blocking SEMA4D's inhibitory signal to dendritic cells, promoting the formation of organized immune centers (TLS) that amplify T cell responses [3][4][5]. - The presence of TLS has been associated with better clinical outcomes and responses to immune checkpoint therapy, making pepinemab a potential solution for "cold" tumors [4][5]. Ongoing Research - Evaluation of pepinemab in the neoadjuvant setting for head and neck cancer is ongoing, with results expected to be reported at upcoming scientific meetings [6].

Core Insights - Pepinemab, a Semaphorin 4D blocking immunotherapy, shows promise in enhancing immune responses and improving survival in patients with metastatic melanoma and head and neck cancer [1][2][4] Company Overview - Vaccinex, Inc. is a clinical-stage biotechnology company focused on innovative treatments for cancer and Alzheimer's disease through the inhibition of Semaphorin 4D [2][8] - The lead drug candidate, pepinemab, is designed to block SEMA4D, which is believed to prevent immune cell infiltration in tumors and trigger inflammation in neurodegenerative diseases [7][8] Clinical Data and Presentations - New data on pepinemab's mechanism to enhance immune responses will be presented at the 2025 Annual Meeting of the American Association for Cancer Research (AACR) [2][3] - Pepinemab has been shown to enhance the maturity of tertiary lymphoid structures (TLS) and correlate with longer recurrence-free survival when combined with immune checkpoint inhibitors in metastatic melanoma patients [5][6] Mechanism of Action - Pepinemab facilitates immune cell interactions within organized centers of immunity, known as tertiary lymphoid structures, by blocking the SEMA4D inhibitory signal to dendritic cells [3][4] - The presence of TLS has been associated with clinical benefits and positive responses to immune checkpoint therapy, making pepinemab a potential solution for inducing TLS in "cold" tumors [4][5] Ongoing Studies - Evaluation of pepinemab in the neoadjuvant setting for head and neck cancer is ongoing, with results expected to be reported at upcoming scientific meetings [6]

Core Viewpoint - Vaccinex, Inc. has decided to delist its common stock from Nasdaq following a suspension of trading since December 18, 2024, due to a notice from the Nasdaq Hearings Panel [1][2] Company Overview - Vaccinex, Inc. is a clinical-stage biotechnology company focused on treating neurodegenerative diseases and cancer by inhibiting SEMA4D, which is believed to trigger damaging inflammation [1][4] - The company's lead product, pepinemab, is designed to block SEMA4D and is being evaluated for Alzheimer's disease and various cancers [4][7] Delisting Details - The company plans to file a Form 25 with the Securities and Exchange Commission around March 17, 2025, to officially remove its common stock from Nasdaq [2] - The decision to delist follows a notice from Nasdaq regarding the delisting of the company's securities [2] Product Development Focus - Vaccinex aims to continue the development of pepinemab through partnerships, grants, and other financing avenues [3] - Pepinemab has been studied in clinical trials for Alzheimer's disease and is also being evaluated in combination therapies for cancer, including studies with KEYTRUDA® and BAVENCIO® [4][5]